Check out the companies making the biggest moves midday: Inspire Medical Systems , ResMed — Inspire Medical Systems and ResMed, which manufacture devices to treat obstructive sleep apnea, dropped 14% and 11%, respectively, following Friday’s news that Eli Lilly ‘s weight loss drug tirzepatide reduced the severity of the condition. Eli Lilly also said it applied for approval from the Food and Drug Administration for the drug’s treatment of sleep apnea. Eli Lilly’s stock advanced 2%. RXO — Shares jumped 23% after the freight company said it struck a deal to buy Coyote Logistics from UPS for more than $1 billion. UPS was up 1.5%. Alnylam Pharmaceuticals — The clinical-stage therapeutics company soared 37% after a phase three study found that its drug vutrisiran showed a statistically significant reduction in the number of deaths and cardiovascular events in patients with ATTR amyloidosis with cardiomyopathy. Nvidia — Shares shed nearly 5%. Nvidia’s latest decline adds to last week’s drop of 4% when it snapped its eight-week winning streak. The artificial intelligence darling had briefly dethroned Microsoft as the most valuable company in the U.S. last week. Affirm — The buy now, pay later stock popped 10% after Goldman Sachs assumed coverage of the name at a buy rating. Analyst Will Nance cited the stock’s strong fundamentals, including its differentiated credit underwriting approach, as catalysts for the name. Cinemark — Shares of the movie theater chain rose more than 5%. Roth MKM upgraded Cinemark to a buy from a neutral rating, saying that headwinds should soon shift to “very attractive tailwinds.” The firm also cited “meaningful box office improvement.” Anheuser-Busch InBev — The brewing company’s shares rose around 3% after UBS upgraded the stock to buy from neutral. The bank noted that Anheuser-Busch is “at the cusp of delivering the ideal consumer staples growth profile,” citing an inflection point in growth, margins and cash returns. IBM — The stock spiked close to 3% after Goldman Sachs initiated coverage with a buy rating and a price target of $200, which implies 16% upside from Friday’s close. The firm said the legacy tech company is on track to sustain long-term revenue and free-cash-flow growth, which are being driven by growth in AI products and services, market share gains in consulting and growth in its core software portfolio. Ryder System — Shares of
CNBC
The full article is available here. This article was published at CNBC Finance.
Comments are closed for this article!